Actionable news
0
All posts from Actionable news
Actionable news in RNN: REXAHN PHARMACEUTICALS Inc,

Prospectus [Rule 424(b)(5)]

Filed Pursuant to Rule 424(b)(5)

SUBJECT TO COMPLETION, DATED NOVEMBER 5, 2015

The information in this preliminary prospectus is not complete and may be changed. This preliminary prospectus is not an offer to sell these securities and we are not soliciting to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Preliminary Prospectus Supplement

shares of common stock

Warrants to purchase shares of common stock

Pursuant to this prospectus supplement and the accompanying prospectus, we are offering shares of our common stock, par value $0.0001 per share, and common stock purchase warrants, or warrants, to purchase up to shares of our common stock. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase of a share of common stock. The warrants have an exercise price of $ per whole share of common stock. Each unit will be sold to investors in this offering at a negotiated price of $ per unit. The shares of common stock and warrants will be issued separately but can only be purchased together in this offering.

Our common stock is listed on the NYSE MKT under the symbol “RNN.” On November 5, 2015, the last reported sale price of our common stock on the NYSE MKT was $0.50 per share. The warrants are not and will not be listed on any national securities exchange or other trading market.

Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-4 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

We have retained Rodman & Renshaw, a unit of HC Wainwright & Co., LLC, or Wainwright or the placement agent, to act as placement agent in connection with the units offered by this prospectus supplement. The placement agent has agreed to use its reasonable efforts to sell the securities offered by this prospectus supplement. We have agreed to pay the placement...


More